Catalyst
Slingshot members are tracking this event:
Catabasis Pharma (CATB) Presents Part B of Phase 2 MoveDMD Trial Evaluating Edasalonexent in Boys with Duchenne Muscular Dystrophy (DMD)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CATB |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 25, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Part B, Phase 2, Movedmd, Edasalonexent, Duchenne Muscular Dystrophy
